Achieve life sciences announces data from cytisinicline orca-v1 program to be presented at society of general internal medicine (sgim) annual meeting

Seattle and vancouver, british columbia, may 17, 2024 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced data from the phase 2 orca-v1 vaping cessation trial will be presented today, friday, may 17, 2024, at the society of general internal medicine (sgim) annual meeting being held in boston, ma.
GM Ratings Summary
GM Quant Ranking